DDInter1471 DDInter1676
Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s. Pindolol was granted FDA approval on 3 September 1982.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Pindolol {u} (Compound) resembles {v} (Compound) Betaxolol
Pindolol {u} (Compound) resembles {v} (Compound) Atenolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Pindolol {u} (Compound) treats {v} (Disease) hypertension
Pindolol {u} (Compound) binds {v} (Gene) HTR1A
Pindolol {u} (Compound) upregulates {v} (Gene) TBP
Pindolol {u} (Compound) downregulates {v} (Gene) PTK2B
Pindolol {u} (Compound) causes {v} (Side Effect) Dyspepsia
Pindolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Pindolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Pindolol (Compound) resembles Betaxolol (Compound)
Pindolol (Compound) resembles Atenolol (Compound)
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Pindolol (Compound) treats hypertension (Disease)
Pindolol (Compound) binds HTR1A (Gene)
Pindolol (Compound) upregulates TBP (Gene)
Pindolol (Compound) downregulates PTK2B (Gene)
Pindolol (Compound) causes Dyspepsia (Side Effect)
Pindolol may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Pindolol may cause a minor interaction that can limit clinical effects when taken with Magaldrate